Literature DB >> 9237711

Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines.

R S Daum1, D Hogerman, M B Rennels, K Bewley, F Malinoski, E Rothstein, K Reisinger, S Block, H Keyserling, M Steinhoff.   

Abstract

Six pentavalent pneumococcal conjugate vaccines (Pn-CRM197) were evaluated among 400 infants. The vaccines differed in saccharide chain length (oligosaccharide [OS] or polysaccharide [PS]) and saccharide quantity (0.5, 2, or 5 microg). Subjects were randomized into groups 1-6 (Pn-CRM197 recipients) or 7 (controls) for immunization at 2, 4, and 6 months of age. Pn-CRM197 were well tolerated and elicited mean antibody concentrations that exceeded those in controls for all 5 capsular serotypes. PS formulations were generally more immunogenic than their OS counterparts. For PS vaccines, a dose-response was documented (5 microg > 2 microg > 0.5 microg), but the differences between the 5- and 2-microg formulations were insignificant. The mean anti-PRP antibody concentration was significantly higher among Pn-CRM197 recipients. It is concluded that PS vaccines are more immunogenic than OS vaccines. The improved immunogenicity from Haemophilus type b oligosaccharide conjugate (HbOC) vaccine when given with Pn-CRM197 suggests that a decreased dose of HbOC vaccine may be sufficient to elicit protection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237711     DOI: 10.1086/514063

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f).

Authors:  Sally A Quataert; Kate Rittenhouse-Olson; Carol S Kirch; Branda Hu; Shelley Secor; Nancy Strong; Dace V Madore
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

2.  Determination of the glycation sites of Bacillus anthracis neoglycoconjugate vaccine by MALDI-TOF/TOF-CID-MS/MS and LC-ESI-QqTOF-tandem mass spectrometry.

Authors:  Farid Jahouh; Shu-jie Hou; Pavol Kováč; Joseph H Banoub
Journal:  J Mass Spectrom       Date:  2011-10       Impact factor: 1.982

Review 3.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

Review 4.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.

Authors:  Simona Rondini; Francesca Micoli; Luisa Lanzilao; Christine Hale; Allan J Saul; Laura B Martin
Journal:  Clin Vaccine Immunol       Date:  2011-01-19

6.  Assignment of weight-based immunoglobulin G1 (IgG1) and IgG2 units in antipneumococcal reference serum lot 89-S(F) for pneumococcal polysaccharide serotypes 1, 4, 5, 7F, 9V, and 18C.

Authors:  Daniel J Sikkema; Nancy A Ziembiec; Thomas R Jones; Stephen W Hildreth; Dace V Madore; Sally A Quataert
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

7.  Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.

Authors:  Tyler D Moeller; Kevin B Weyant; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

8.  Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.

Authors:  Zhigang Jin; Chiayung Chu; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines.

Authors:  Kay Lockyer; Fang Gao; Jeremy P Derrick; Barbara Bolgiano
Journal:  Vaccine       Date:  2015-01-29       Impact factor: 3.641

Review 10.  Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review.

Authors:  R K Lucinde; G Ong'ayo; C Houlihan; C Bottomley; D Goldblatt; J A G Scott; K E Gallagher
Journal:  Vaccine       Date:  2021-07-31       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.